Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Completed 2

Sponsor Class

OTHER 23NIH 5INDUSTRY 5NETWORK 2

Study Type

Interventional 5

Sponsor

Cancer Type

Lymphoid 3Thoracic 1

Conditions

Parkinson Disease 4, Autosomal Dominant Lewy Body 2Small Cell Lung Carcinoma 1Neoplasms 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Hodgkin Disease 1

Interventions

pembrolizumab 604Carboplatin 372Paclitaxel 282Cisplatin 267Gemcitabine 252Pemetrexed 193Bevacizumab 190Docetaxel 185Nivolumab 181Injections 167Cyclophosphamide 147atezolizumab 138Fluorouracil 133Capecitabine 133Oxaliplatin 132Dexamethasone 127Fulvestrant 113durvalumab 112130-nm albumin-bound paclitaxel 110fludarabine 101Cetuximab 100Leucovorin 97Rituximab 94venetoclax 90Lenalidomide 83enzalutamide 77Prednisone 76Azacitidine 74Irinotecan 72Ipilimumab 72

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
INDUSTRY × etoposide phosphate × 1 year × Clear all
NCT04663347 2026-06-02

EPCOREâ„¢ NHL-2

Genmab

Phase 1/2 Active not recruiting
543 enrolled
Lymphoid

Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse

NCT06230224 2026-05-11

OLYMPIA-4

Regeneron Pharmaceuticals

Phase 3 Active not recruiting
216 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell

NCT03407144 2026-02-19

MK-3475-667

Merck Sharp & Dohme LLC

Phase 2 Active not recruiting
340 enrolled
Lymphoid

Hodgkin Disease

NCT02964013 2025-10-14

KEYVIBE-001

Merck Sharp & Dohme LLC

Phase 1 Completed
474 enrolled 39 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body, Neoplasms

NCT04924101 2025-07-23

KEYNOTE-B99

Merck Sharp & Dohme LLC

Phase 2 Completed
126 enrolled
Thoracic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡